Cancer Chemotherapy and Pharmacology

Volume 16 1986

Edited by

S.K. CARTER and T. McELWAIN

Editorial Board

M. Acton Menlo Park
P. Alberto Geneva
R. H. Blum New York
M. Boiron Paris
H. Calvert Sutton
R. L. Comis Syracuse
T. Connors Carshalton
R. C. Coombes Sutton
S. Eckhardt Budapest
B. W. Fox Manchester
R. M. Fox Sydney
S. Garattini Milano
M. Ghione Milano
H. Hansen Copenhagen
K. Karrer Vienne
D. L. Kisner Bethesda
J. Laszlo Durham
R. B. Livingston Seattle
J. S. Macdonald Bethesda
J. G. McVie Amsterdam
F. M. Muggia New York
M. Ogawa Tokyo
P. Martin Marseille
S. Pavlovsky Buenos Aires
P. Potier Gif-sur-Yvette
P. Reizenstein Stockholm
E. Robinson Haifa
M. Rozencweig Brussells
C. G. Schmidt Essen
H. J. Senn St. Gallen
J. F. Smyth Edinburgh
A. Trouet Brussells
S. Tsukagoshi Tokyo
U. Umezawa Tokyo
F. A. Valeriote Detroit
L. M. van Putten Rijswijk
P. Wilkinson Manchester
G. Wu Huan-Hsin Peking

Springer International

Cancer Chemotherapy and Pharmacology

This journal was founded in 1978. Editors: S. K. Carter, T. McElwain. Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page, or a minimum of US $ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Other regulations: Authors publishing in this journal can, under certain conditions, benefit from library and photocopy fees collected by VG WORT. Authors of German nationality and those resident in the Federal Republic of Germany or Berlin (West), as well as citizens of Austria, Switzerland and member countries of the European Community, may apply to Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß

© Springer-Verlag Berlin Heidelberg 1986

Contents of volume 16

Aapro MS, see Abele R, et al. 182
Aapro M, see Kessler JF, et al. 282
Abdallah RM, see Meadows GG, et al. 229
Abele R, Aapro MS, Haefliger J-M, Alberto P: Phase I study of cyclohexylamine and lysine salt of mafosfamide 182
Ackerly CC, see Stewart JA, et al. 287
Aherne GW, see Burton NK 83
Akagi T, see Matsumura Y, et al. 176
Alberto P, Rozencweig M, Clavel M, Siegenthaler P, Cavalli F, Gundersen S, Bruntsch U, Renard J, Pinedo H: Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma 78
Alberto P, see Abele R, et al. 182
Alberts DS, see Dorr RT, et al. 91
Alberts DS, see Kessler JF, et al. 282
Almersjö O, see Berne MHO, et al. 237
Anderson CC, Goldstone AH, Souhami RL, Linch DC, Harper PG, McLennan KA, Jones M, Machin SJ, Jelliffe AM, Cawley JC, Richards JDM: Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma 170
Angelelli B, see Pannuti F, et al. 295
Arcamone F, see Zini G, et al. 107
Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T: Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases 300
Averbuch SD, Clawson RE, Bachur NR, Felsted RL: Cellular pharmacology and antitumor activity of *N*-(*p*-azidobenzoyl)daunorubicin, a photoactive anthracycline analogue 211

Bachur NR, see Averbuch SD, et al. 211
Bagshawe KD, see Crawford SM, et al. 306
Barbet J, see Rahmani R, et al. 223
Barbieri B, see Rahman A, et al. 22
Basseches PJ, see Powis G, et al. 43
Beaujean F, see Hartmann O, et al. 165
Benhamou E, see Hartmann O, et al. 165
Berne MHO, Gustavsson BG, Almersjö O, Spears PC, Frösing R: Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma 237
Biron P, see Ardiet C, et al. 300
Bishop J, see Raghavan D, et al. 160, 308
Bradner WT, see Schurig JE, et al. 243
Broggini M, Erba E, Morasca L, Horgan C, D'Incalci M: In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma 125
Bruntsch U, see Alberto P, et al. 78
Buamah PK, Skillen AW, Ward AM: Serum alpha fetoprotein kinetics in hepatocellular carcinoma. A case for cessation of therapy 75
Budman DR, see Kreis W, et al. 70
Burton NK, Aherne GW: The effect of cotrimoxazole on the absorption of orally administered 6-mercaptopurine in the rat 83

Camaggi CM, see Pannuti F, et al. 295
Cano J-P, see Rahmani R, et al. 223
Carsana R, see Formelli F, et al. 15
Casazza AM, see Rahman A, et al. 22
Cavalli F, see Alberto P, et al. 78
Cawley JC, see Anderson CC, et al. 170
Chase J, see Kessler JF, et al. 282
Clausen N, see Schrøder H, et al. 190
Clavel M, see Alberto P, et al. 78
Clawson RE, see Averbuch SD, et al. 211
Coates A, see Raghawan D, et al. 160, 308
Comparsi R, see Pannuti F, et al. 295
Cowan JD, see Miller TP, et al. 67
Crawford SM, Rustin GJS, Bagshawe KD: Acute neurological toxicity of intrathecal cytosine arabinoside. A case report 306

Dale BM, see Reece PA, et al. 194
Deeb G, see Gaver RC 201
Demard F, see Thyss A, et al. 64
D'Incalci M, see Broggini M, et al. 125
Dixon CW, see Gaver RC, et al. 207
Donaldson J, see Workman P, et al. 9, 308
Dorr RT, Alberts DS, Soble M: Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone 91
Dufour M, see Lazarus P, et al. 148

Eckhardt S, see Erdélyi-Tóth V, et al. 257
Eckhardt S, see Kerpel-Fronius S, et al. 264
Erba E, see Broggini M, et al. 125
Erdélyi-Tóth V, Kerpel-Fronius S, Kanyár B, Eckhardt S: Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG) 257
Erdélyi-Tóth V, see Kerpel-Fronius S, et al. 264
Ershler WB, see Gamelli RL, et al. 153

Fathalla SAK, see Harpur ES, et al. 139
Felsted RL, see Averbuch SD, et al. 211
Ferrans VJ, see Herman EH 102
Feun LG, see Lu K, et al. 156
Feun LG, see Savaraj N, et al. 292
Fields WS, see Savaraj N, et al. 292
Flamant F, see Hartmann O, et al. 165
Florczyk AP, see Schurig JE, et al. 243
Formelli F, Carsana R, Pollini C: Comparative pharmacokinetics and metabolism of doxorubicin and 4-demetoxy-4'-O-methyldoxorubicin in tumor-bearing mice 15
Foster RS, see Gamelli RL, et al. 153
Fox R, see Raghavan D, et al. 160, 308
Freeman J, see Kreis W, et al. 70
Frösing R, see Berne MHO, et al. 237
Fujimoto T, see Tsurusawa M, et al. 277
Fumagalli A, see Rahman A, et al. 22

Gamelli RL, Ershler WB, Hacker MP, Foster RS: The effect of disulfiram on cyclophosphamide-mediated myeloid toxicity 153
Ganjei A, see Rahman A, et al. 28
Gaver RC, Deeb G: High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine 201
Gaver RC, Dixon CW, Smyth RD: A radioimmunoassay procedure for tallysomycin S_{10b} in human plasma and urine 207
Geyer H, see Runge H-M, et al. 58
Goldstone AH, see Anderson CC, et al. 170
Gordon GR, see Streeter DG, et al. 247
Gouyette A, Hartmann O, Pico J-L: Pharmacokinetics of high-dose melphalan in children and adults 184
Greist A, see Kreis W, et al. 70
Griswold DP, see Hook KE, et al. 116
Grygiel J, see Raghavan D, et al. 160, 308
Guéritte F, see Rahmani R, et al. 223
Gundersen S, see Alberto P, et al. 78
Gunnarsson PO, see Hartley-Asp B, et al. 85
Gustavsson BG, see Berne MHO, et al. 237
Gutterman JU, see Rosenblum MG, et al. 273
Gyergyay F, see Kerpel-Fronius S, et al. 264

Hacker MP, see Gamelli RL, et al. 153
Haefliger J-M, see Abele R, et al. 182
Hamelehle KL, see Roberts BJ, et al. 95
Harper PG, see Anderson CC, et al. 170
Harpur ES, Langdon P, Fathalla SAK, Ishmael J: The antitumour effect and toxicity of *cis*-platinum and *N*-methylformamide in combination 139
Harris RN, see Powis G, et al. 43

Hartley-Asp B, Gunnarsson PO, Liljekvist J: Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line 85
Hartmann O, Kalifa C, Benhamou E, Patte C, Flamant F, Jullien C, Beaujean F, Lemerle J: Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation 165
Hartmann O, see Gouyette A, et al. 184
Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM: The effect of dose on the bioavailability of oral etoposide 178
Hepburn PJ, Masters JRW: Influence of clonogenic assay methodology on measurement of drug sensitivities in vitro 80
Herman EH, Ferrans VJ: Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits 102
Hindy I, see Kerpel-Fronius S, et al. 264
Hirata M, see Kasai H, et al. 55
Hollander D, see Said HM 121
Hook KE, Nelson JM, Roberts BJ, Griswold DP, Leopold WR: Cell cycle effects of trimetrexate (CI-898) 116
Horgan C, see Broggini M, et al. 125

Isabel G, see Lazarus P, et al. 148
Ishmael J, see Harpur ES, et al. 139

Jelliffe AM, see Anderson CC, et al. 170
Jeney A, Kopper L, Nagy P, Lapis K, Süli-Vargha H, Medzihradszky K: Antitumor action of *N*-(2-chloroethyl)-*N*-nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments 129
Joel SP, see Harvey VJ, et al. 178
Johl JS, see Streeter DG, et al. 247
Johnston A, see Harvey VJ, et al. 178
Jones M, see Anderson CC, et al. 170
Jones SE, see Miller TP, et al. 67
Jullien C, see Hartmann O, et al. 165
Jurlina JL, see Paxton JW 253
Just S, see Rahmani R, et al. 223

Kalifa C, see Hartmann O, et al. 165
Kanyár B, see Erdélyi-Tóth V, et al. 257
Kanyár B, see Kerpel-Fronius S, et al. 264
Kasai H, Tonda K, Hirata M: Potentiation of antitumor activity of 1-phthalidyl 5-fluorouracil by acetazolamide 55
Katano N, see Tsurusawa M, et al. 277
Kerpel-Fronius S, see Erdélyi-Tóth V, et al. 257
Kerpel-Fronius S, Erdélyi-Tóth V, Gyergyay F, Hindy I, Mechl Z, Nekulová M, Somfai-Relle S, Kovács P, Ujj Gy, Kanyár B, Eckhardt S: Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG) 264
Kessler JF, Alberts DS, Plezia PM, Wilson V, Chase J, Aapro M, Surwit EA: An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patients 282
Kevill L, see Kreis W, et al. 70
Kooistra KL, see Rosenow S, et al. 35
Kopper L, see Jeney A, et al. 129
Kotasek D, see Reece PA, et al. 194
Kovács P, see Kerpel-Fronius S, et al. 264
Krakoff IH, see Stewart JA, et al. 287
Kreis W, Budman DR, Schulman P, Freeman J, Greist A, Nelson RL, Marks M, Kevill L: Clinical pharmacology of vinzolidine 70

Langdon P, see Harpur ES, et al. 139
Lapis K, see Jeney A, et al. 129
Lazarus P, Dufour M, Isabel G, Panasci LC: In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays 148
Lazzati M, see Zini G, et al. 107
Lehnert S: In vivo toxicity of phenothiazines to cells of a transplantable tumor 269
Lemerle J, see Hartmann O, et al. 165
Leopold WR, see Roberts BJ, et al. 95
Leopold WR, see Hook KE, et al. 116
Liljekvist J, see Hartley-Asp, et al. 85
Linch DC, see Anderson CC, et al. 170
Loo TL, see Lu K, et al. 156
Loo TL, see Savaraj N, et al. 292
Lu K, Savaraj N, Yap B-S, Feun LG, Umsawasdi T, Loo TL: Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 *H*-imidazol-2-yl)hydrazone]dihydrochloride 156
Lu K, see Savaraj N, et al. 292

Machin SJ, see Anderson CC, et al. 170
Marks M, see Kreis W, et al. 70
Martin M, see Rahmani R, et al. 223
Masters JRW, see Hepburn PJ 80
Matsumura Y, Tsushima T, Ozaki Y, Yoshimoto J, Akagi T, Obama T, Nasu Y, Ohmori H: Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors 176
Matsuoka H, see Tsurusawa M, et al. 277
McLennan KA, see Anderson CC, et al. 170
Meadows GG, Abdallah RM, Starkey JR: Interaction between specific dietary factors and experimental chemotherapy of metastatic melanoma 229
Mechl Z, see Kerpel-Fronius S, et al. 264
Medzihradszky K, see Jeney A, et al. 129
Milano G, see Thyss A, et al. 64
Miller TP, Cowan JD, Neilan BA, Jones SE: A phase II study of bisantrene in malignant lymphomas. A southwest oncology group study 67
Moore DJ, Powis G: Disposition and metabolism of the antitumor glycoside phyllanthoside in mouse and beagle dog 218
Morasca L, see Broggini M, et al. 125
Morgan JE, see Workman P, et al. 9, 308
Morris RG, see Reece PA, et al. 194
Murray SL, see Slater LM, et al. 50
Myers CF, see Stewart JA, et al. 287

Nagy P, see Jeney A, et al. 129
Nasu Y, see Matsumura Y, et al. 176
Neefe JR, see Rahman A, et al. 28
Neilan BA, see Miller TP, et al. 67
Nekulová M, see Kerpel-Fronius S, et al. 264
Newman RA, see Stewart JA, et al. 287
Nelson JM, see Hook KE, et al. 116
Nelson RL, see Kreis W, et al. 70
Neulen J, see Runge H-M, et al. 58
Nwankwoala RNP, West WL: Calmodulin and alpha tocopherol as additional binding sites for doxorubicin 133

Obama T, see Matsumura Y, et al. 176
Ohmori H, see Matsumura Y, et al. 176
Østergaard E, see Schrøder H, et al. 190
Ozaki Y, see Matsumura Y, et al. 176

Pacciarini MA, see Pannuti F, et al. 295
Panasci LC, see Lazarus P, et al. 148
Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Angelelli B, Pacciarini MA: Low dose oral administration of 4-demethoxy-daunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study 295
Patte C, see Hartmann O, et al. 165
Paxton JW, Jurlina JL: Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analog, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)-phenylamino]-4-acridinecarboxamide in rabbits 253
Peters JH, see Streeter DG, et al. 247
Pfleiderer A, see Runge H-M, et al. 58
Philip T, see Ardiet C, et al. 300
Pico J-L, see Gouyette A, et al. 184

Pinedo H, see Alberto P, et al. 78
Plezia PM, see Kessler JF, et al. 282
Pollini C, see Formelli F, et al. 15
Powis G, see Rosenow S, et al. 35
Powis G, Harris RN, Basseches PJ, Santone KS: Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse 43
Powis G, see Moore DJ 218
Pressler T, see Schrøder H, et al. 190

Raghavan D, Bishop J, Sampson D, Grygiel J, Woods R, Coates A, Fox R: Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion 160, 308
Rahmani R, Guéritte F, Martin M, Just S, Cano J-P, Barbet J: Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats 223
Rahman A, Fumagalli A, Barbieri B, Schein PS, Casazza AM: Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes 22
Rahman A, Ganjei A, Neefe JR: Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes 28
Rebattu P, see Ardiet C, et al. 300
Reece PA, Kotasek D, Morris RG, Dale BM, Sage RE: The effect of food on oral melphalan absorption 194
Renard J, see Alberto P, et al. 78
Renée N, see Thyss A, et al. 64
Richards JDM, see Anderson CC, et al. 170
Riso A, see Rosenblum MG, et al. 273
Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR: In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721) 95
Roberts BJ, see Hook KE, et al. 116
Rosenblum MG, Riso A, Gutterman JU: Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: Dependence of biological effect on administration route 273
Rosenow S, Kooistra KL, Powis G, Van Dyke RA: Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane 35
Rozencweig M, see Alberto P, et al. 78
Runge H-M, Teufel G, Neulen J, Geyer H, Pfleiderer A: In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy 58
Rustin GJS, see Crawford SM, et al. 306

Sage RE, see Reece PA, et al. 194
Said HM, Hollander D: Inhibitory effect of bile salts on the enterohepatic circulation of methotrexate in the unanesthetized rat: Inhibition of methotrexate intestinal absorption 121
Sampson D, see Raghavan D, et al. 160
Santone KS, see Powis G, et al. 43
Sasaki K, see Tsurusawa M, et al. 277
Savaraj N, see Lu K, et al. 156
Savaraj N, Feun LG, Lu K, Wallace S, Fields WS, Loo TL: Clinical pharmacology of intracarotid etoposide 292
Schein PS, see Rahman A, et al. 22
Schneider M, see Thyss A, et al. 64
Schrøder H, Clausen N, Østergaard E, Pressler T: Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment 190
Schulman P, see Kreis W, et al. 70
Schurig JE, Florczyk AP, Bradner WT: The mouse as a model for predicting the myelosuppressive effects of anticancer drugs 243
Sebolt JS, see Roberts BJ, et al. 95
Siegenthaler P, see Alberto P, et al. 78
Skillen AW, see Buamah PK, et al. 75
Slater LM, Murray SL, Wetzel MW, Sweet P, Stupecky M: Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance 50
Slevin ML, see Harvey VJ, et al. 178
Smyth RD, see Gaver RC, et al. 207
Soble M, see Dorr RT, et al. 91
Somfai-Relle S, see Kerpel-Fronius S, et al. 264
Souhami RL, see Anderson CC, et al. 170
Spears PC, see Berne MHO, et al. 237
Starkey JR, see Meadows GG, et al. 229
Stewart JA, Ackerly CC, Myers CF, Newman RA, Krakoff IH: Clinical and clinical pharmacologic studies of 2-amino-1,3,4-thiadiazole (A-TDA: NSC 4728) 287
Streeter DG, Johl JS, Gordon GR, Peters JH: Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells 247
Strocchi E, see Pannuti F, et al. 295
Stupecky M, see Slater LM, et al. 50
Süli-Vargha H, see Jeney A, et al. 129
Surwit EA, see Kessler JF, et al. 282
Sweet P, see Slater LM, et al. 50

Talbot K, see Workman P, et al. 1, 308
Talbot K, see Workman P, et al. 9, 308
Teufel G, see Runge H-M, et al. 58
Thyss A, Milano G, Renée N, Vallicioni J, Schneider M, Demard F: Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer 64
Tonda K, see Kasai H, et al. 55
Tranchand B, see Ardiet C, et al. 300
Tsurusawa M, Sasaki K, Matsuoka H, Yamamoto Y, Katano N, Fujimoto T: Flow cytometric analysis of marrow cell kinetics in children treated with high-dose MTX and CF rescue 160
Tsurusawa M, Sasaki K, Matsuoka H, Yamamoto Y, Katano N, Fujimoto T: Flow cytometric analysis of marrow cell kinetics in children treated with high-dose MTX and CF rescue 277
Tsushima T, see Matsumura Y, et al. 176
Twentyman PR, see Workman P, et al. 9, 308

Ujj Gy, see Kerpel-Fronius S, et al. 264
Umsawasdi T, see Lu K, et al. 156

Vallicioni J, see Thyss A, et al. 64
Van Dyke RA, see Rosenow S, et al. 35
Vicario GP, see Zini G, et al. 107

Wallace S, see Savaraj N, et al. 292
Ward AM, see Buamah PK, et al. 75
West WL, see Nwankwoala RNP 133
Wetzel MW, see Slater LM, et al. 50
White RAS, see Workman P, et al. 1, 308
Wilson V, see Kessler JF, et al. 282
Woods R, see Raghavan D, et al. 160, 308
Workman P: Pharmacokinetics in experimental and clinical chemotherapy 198
Workman P, Morgan JE, Talbot K, Wright KA, Donaldson J, Twentyman PR: CB 1954 revisited. II. Toxicity and antitumour activity 9
Workman P, Morgan JE, Talbot K, Wright KA, Donaldson J, Twentyman PR: *Erratum to:* CB 1954 revisited. II. Toxicity and antitumour activity 308
Workman P, White RAS, Talbot K: CB 1954 revisited. I. Disposition kinetics and metabolism 1
Workman P, White RAS, Talbot K: *Erratum to:* CB 1954 revisited. I. Disposition kinetics and metabolism 308
Wright KA, see Workman P, et al. 9, 308
Wrigley PFM, see Harvey VJ, et al. 178

Yamamoto Y, see Tsurusawa M, et al. 277
Yap B-S, see Lu K, et al. 156
Yoshimoto J, see Matsumura Y, et al. 176

Zini G, Vicario GP, Lazzati M, Arcamone F: Disposition and metabolism of [14-^{14}C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-^{14}]daunorubicin HCl in the rat. A comparative study 107

Subject index of volume 16

Adriamycin 176
Advanced neuroblastoma 165
Alkylating agent 257
Alphafetoprotein kinetics 75
Alpha tocopherol 133
Aminothiadiazole 287
Amsacrine 253
Anthracycline 211, 247
- derivatives 15
Antiemetic combination chemotherapy 282

Bioavailability 178
Bisantrene 67, 156
Bone marrow rescue 170

Calmodulin 133
Carboplatin 201
CB 1954 1, 9
Cell death 85
Chemotherapy 229
Children 190
Chlorambucil 85
6-(bis-(chloroethyl)-amino)-6-deoxy-D-glucose 148
CI-940 95
Cisplatin 91
Clinical chemotherapy 198
Clinical pharmacokinetics 64, 156
Clonogenic assay 80
Cotrimaxole 83
Cyclohexylamine 182
Cyclophosphamide 35, 153

Daunorubicin 107
- cardiotoxicity 102
Diacetyldianhydrogalacticol 257, 264
Dieting 229
Disulfiram 153
Dose 264
Doxifluridine 78
Doxorubicin 22, 28, 133
Drug resistance 50
Drug sensitivity 80

Endocrine therapy 58
4-Epi-Adriamycin 176
Etoposide 178

Flow cytometry 125, 277
5-Fluorouracil 64, 237

Haemorrhagic cystilis 153
Halothane 35
Head and neck cancer 64
Hepatocellular carcinoma 75
High-dose chemotherapy 170
High-dose MTX 277
High-dose melphalan 165, 300
Human tumor stem cell assay 58

ICRF-187 95
Idarubicin 107
- pharmacokinetics 295
Immunotoxicity 28
gamma-Interferon 273
Intestinal absorption 121
Intracarotid infusion VP16 292
Intravesical chemotherapy 176

Leukemia 50
- drug metabolism 43
Lewis lung carcinoma 125
Liposomes 22

Mafosfamide 182
Marrow cell kinetics 277
Medroxyprogesteroneacetate 58
Melanoma 78, 229
Melphalan 91, 148, 184
- absorption 194
Metabolism 85
Methotrexate 121, 190, 237
N-Methylformamide 139
Mitoxantrone 91
Myeloid toxicity 153
Myelosuppression 243

Neurotoxicity 306

Omtestoma 121
Ovarian carcinoma 58

PD 114,721 95
Pharmacokinetics 125, 160, 184, 190, 198, 218, 223, 257, 295, 300
- of vinzolidine 70
Pharmacology 292
Phase I study 160
Phenothiazines 269
Phthalidyl 5-fluorouracil-acetazolamide 55
Phyllanthoside 218
Plasma concentration 264
cis-Platinum 139
Polypeptide hormone fragments 129
Prednimustine 85
Prednisolone 85

Radioimmunoassay 207
Rat 121
Resistant lymphoma 170

Superficial bladder cancer 176

Tallysomycin S10b 207
Tamoxifen 58
Thymidylate synthetase 237
Toxicity 264, 269
Trimetrexate 116

Verapamil 50
Vesicants 91
Vinca alkaloids 223
VP-16-213 50